CHF 27 million investment significantly bolsters Boehringer's ADC portfolio, driven by its subsidiary, NBE Therapeutics, to achieve the company’s ...

ZOLAR is a first-in-human, proof-of-concept and biodistribution trial that uses positron emission tomography (PET) to evaluate olaratumab, a monoclonal antibody, as a therapeutic radiopharmaceutical ...

In 2024, casualties from landmines and unexploded ordinance surged by 22% (Landmine Monitor 2024). Figures the ICRC have gathered from early 2025 indicate that the rise in victims will further ...